Program

Tafalgie Therapeutics will participate in the ‘IPOready’ 2024 program, a pre-IPO program organized by Euronext for the 9th consecutive year Tafalgie Therapeutics, a biopharmaceutical research company specializing in research and innovation for treatments to alleviate and prevent acute and chronic pain (inflammatory, postoperative, neuropathic) without side effects is proud to announce that it has been […]

Lire la suite